BioMarin Pharmaceutical Inc. (BMRN)

[chmcnfunds]

Discussion in recent increase in shorts:

BioMarin Pharmaceutical. On top of an 11 percent rise in the previous period, short interest in this San Rafael, Calif.-based company grew about 12 percent to total more than 5.82 million shares. That was the greatest number since March, and it was about four percent of the float. Days to cover was more than three.

This biopharmaceuticals company has a market cap of more than $8 billion. Third-quarter revenue grew less than expected, but BioMarin reaffirmed its full-year guidance. The long-term EPS growth forecast is about 25 percent, though the return on equity and operating margin are both in the red.

Nine of the 22 polled analysts rate the stock at Strong Buy, and another eight also recommend buying shares. The analysts see room for shares to run, as the mean price target is about 23 percent higher than the current share price. But note that shares traded higher than that target back in September.

Shares have pulled back more than eight percent in the past month. The share price still is up more than 19 percent year to date.

Read more: http://www.benzinga.com/news/13/11/4073760/gilead-sciences-leads-in-rising-short-interest-among-biotechs#ixzz2kWoA33Xu
________________________________________________

BMRN